NIKKEI 225
38,079.70 0.00 (0.00%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.67 -0.06 (-0.07%) GOLD FUTURES
2,393.40 -4.60 (-0.19%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,710.25 +1,535.98 (+3.12%)
Mereo BioPharma Group plc (MREO)
After hours:
| Previous close | 2.5800 |
| Open | 2.5600 |
| Bid | 2.6400 x 600 |
| Ask | 2.6700 x 400 |
| Day's range | 2.5250 - 2.6750 |
| 52-week range | 0.9200 - 4.3600 |
| Volume | |
| Avg. volume | 1,635,029 |
| Market cap | 371.681M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Compa
- GlobeNewswire
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partner around the end of 2024 Cash of $57.4 million as of December 31, 2023 expected to fund operations into 2026 LONDON, March 27, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “
- Globe Newswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company’s
